Suppr超能文献

诱导化疗后儿童霍奇金淋巴瘤骨骼(骨髓和骨骼)受累的 F-FDG PET 反应:是否需要特定的反应标准?

F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?

机构信息

Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany

Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.

出版信息

J Nucl Med. 2018 Oct;59(10):1524-1530. doi: 10.2967/jnumed.117.205633. Epub 2018 Apr 13.

Abstract

To determine whether the current F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2). A secondary objective was to observe the influence of the initial uptake intensity (measured as qPET) and initial metabolic tumor volume (MTV) of skeletal lesions on the PET-2 response. The initial PET scans of 1,068 pediatric HL patients from the EuroNet-PHL-C1 trial were evaluated for skeletal involvement by central review. Three types of skeletal lesions were distinguished: PET-only lesions (those detected on PET only), bone marrow (BM) lesions (as confirmed by MRI or BM biopsy), and bone lesions. qPET and MTV were calculated for each skeletal lesion. All PET-2 scans were assessed for residual tumor activity. The rates of complete metabolic response for skeletal and nodal involvement on PET-2 were compared. Of the 1,068 patients, 139 (13%) showed skeletal involvement (44 PET-only, 32 BM, and 63 bone). Of the 139 patients with skeletal involvement, 101 (73%) became PET-2-negative in the skeleton and 94 (68%) became PET-2-negative in the lymph nodes. The highest number of PET-2-negative scans in the skeleton was 42 (95%) in the 44 PET-only patients, followed by 22 skeletal lesions (69%) in the 32 BM patients and 37 (59%) in the 63 bone patients. Lesions that became PET-2-negative showed a lower initial median qPET (2.74) and MTV (2 cm) than lesions that remained PET-2-positive (3.84 and 7 cm, respectively). In this study with pediatric HL patients, the complete response rate for skeletal involvement on PET-2 was similar to that for nodal involvement. Bone flare seemed to be irrelevant. Overall, the current skeletal PET response criterion-comparison with the local skeletal background-is well suited. The initial qPET and MTV of skeletal lesions were predictive of the PET-2 result. Higher values for both parameters were associated with a worse PET-2 response.

摘要

为了确定当前用于霍奇金淋巴瘤(HL)骨骼受累的 F-FDG PET 反应标准是否合适,我们对不同类型的骨骼受累及其在 2 周期化疗后(PET-2)的 PET 反应进行了系统评估。次要目标是观察骨骼病变的初始摄取强度(以 qPET 测量)和初始代谢肿瘤体积(MTV)对 PET-2 反应的影响。来自 EuroNet-PHL-C1 试验的 1068 例儿科 HL 患者的初始 PET 扫描由中央审查评估骨骼受累情况。区分了三种类型的骨骼病变:仅 PET 病变(仅在 PET 上检测到)、骨髓(BM)病变(通过 MRI 或 BM 活检证实)和骨病变。为每个骨骼病变计算了 qPET 和 MTV。所有 PET-2 扫描均评估残留肿瘤活性。比较了骨骼和淋巴结受累的 PET-2 完全代谢反应率。在 1068 例患者中,139 例(13%)有骨骼受累(44 例仅 PET,32 例 BM,63 例骨)。在 139 例骨骼受累患者中,101 例(73%)骨骼 PET-2 阴性,94 例(68%)淋巴结 PET-2 阴性。44 例仅 PET 患者中有 42 例(95%)PET-2 扫描结果最多,32 例 BM 患者中有 22 例(69%)骨骼病变和 63 例骨患者中有 37 例(59%)。变为 PET-2 阴性的病变的初始中位数 qPET(2.74)和 MTV(2cm)低于仍为 PET-2 阳性的病变(分别为 3.84 和 7cm)。在这项儿科 HL 患者的研究中,PET-2 对骨骼受累的完全缓解率与淋巴结受累相似。骨闪光似乎无关紧要。总体而言,当前的骨骼 PET 反应标准-与局部骨骼背景相比-非常适合。骨骼病变的初始 qPET 和 MTV 可预测 PET-2 结果。这两个参数的值越高,PET-2 反应越差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验